Latest Biotech News

The FDA granted accelerated approval to Regeneron’s Otarmeni (lunsotogene parvec-cwha), described as the first gene therapy intended to restore neurosensory function in OTOF-related sensorineural...

Biogen and Eisai said the FDA delayed its decision on subcutaneous Leqembi, pushing the review date to August 24. The original decision timing was later this month, extending uncertainty for a...

Pierre Fabre and Atara Biotherapeutics said the FDA will reconsider Ebvallo (tabelecleucel/tab-cel) after the agency previously rejected the therapy using the same underlying single-arm evidence...

Roche agreed to acquire PathAI for up to $1.05 billion, aiming to accelerate use of AI in diagnostic workflows. Roche will pay $750 million upfront and up to $300 million in milestone-linked...

Angelini Pharma is buying Catalyst Pharmaceuticals for about $4.1 billion in cash, paying $31.50 per share. The all-cash offer represents a premium to Catalyst’s recent trading levels and is...

Researchers at the La Jolla Institute for Immunology (LJI) identified human monoclonal antibodies that neutralize measles virus by blocking viral entry through two essential surface proteins:...

Vyriad said it will showcase its G-Link modular CAR T delivery platform at the American Society of Gene & Cell Therapy (ASGCT) meeting in Boston. The company described G-Link as a plug-and-play...

ParcelBio raised $13 million in seed financing led by Breyer Capital, with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, and others. The company will use the...

Natera raised its 2026 revenue guidance after reporting a 39% year-over-year jump in Q1 revenue driven by growth in clinical oncology testing and women’s health volumes. The company reset its...

Alamar Biosciences became newly publicly traded after a $220 million IPO and reported a Q1 2026 revenue surge that nearly doubled year over year. The proteomics company posted $26.0 million in...

The US FDA agreed to reconsider approval of Atara Biotherapeutics and Pierre Fabre Pharmaceuticals’ off-the-shelf T-cell therapy Ebvallo (tabelecleucel/tab-cel) after a second meeting that walked...

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, adding PER-001 to its ophthalmology development pipeline. The deal includes a $300 million upfront payment and additional...

Roche agreed to acquire PathAI for up to $1.05 billion to expand its digital pathology capabilities and accelerate AI adoption in companion diagnostics. The deal structure calls for a $750 million...

Pacific Biosciences cut the high end of its 2026 revenue guidance by $5 million after reporting flat Q1 revenue tied to softer instrument demand, particularly for its Vega platform, and continued...

Guardant Health reported Q1 2026 revenue of $301.7 million, up 48% year over year, and increased its full-year guidance to $1.30 billion to $1.32 billion. The ramp was driven by continued growth...

Natera increased its 2026 guidance after first-quarter 2026 revenue jumped 39% year over year, reflecting strength across its clinical oncology business and women’s health testing. Management said...

BillionToOne reported Q1 2026 revenue of $108.4 million, up 84% year over year, citing growth across prenatal clinical testing and related services. The company said it accessioned 189,000 tests...

Moonlight AI, a Swiss developer of diagnostic image-analysis software, raised $3.3 million in private financing to expand its dataset linking cytology images to genomic biomarkers. The company...

Odyssey Therapeutics priced an upsized initial public offering at $18 per share to raise about $304 million in gross proceeds, following a prior attempt to go public that was paused earlier. The...

Cellular Origins and Immatics expanded their manufacturing technology collaboration, agreeing to use Cellular Origins’ automated mobile robotic platform, Constellation, for parts of Immatics’ cell...